Cinclus Pharma Boosts 2025 Revenue but Maintains Heavy R&D-Driven Losses

An announcement from Cinclus Pharma Holding AB ( (SE:CINPHA) ) is now available.

Cinclus Pharma reported full-year 2025 net sales of SEK 57.5 million, a sharp increase from the prior year, but continued to post a sizeable operating loss of SEK 199.6 million as it maintained high R&D spending. The company ended the year with cash and cash equivalents of SEK 487.3 million, providing a substantial financial runway despite negative cash flow and reinforcing its ability to continue development activities in its GERD-focused pipeline.

In the fourth quarter, net sales rose to SEK 13.6 million while the operating loss widened slightly to SEK 62.0 million, and the net loss for the quarter reached SEK 61.2 million. Management highlighted a strong liquidity position and has scheduled a series of financial report dates and a webcast in 2026, signaling ongoing transparency to investors and a continued focus on progressing its R&D programs despite current losses.

The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.

More about Cinclus Pharma Holding AB

Cinclus Pharma Holding AB is a Swedish biopharmaceutical company focused on developing treatments for gastroesophageal reflux disease (GERD). The company is heavily R&D driven, with 84% of operating expenses allocated to research and development, and operates with a lean organization of 45 co-workers including employees and in-house consultants.

Average Trading Volume: 43,719

Technical Sentiment Signal: Sell

Current Market Cap: SEK806M

See more data about CINPHA stock on TipRanks’ Stock Analysis page.